MARKETSPERPSLIVE109
Cash
Portfolio
TrendingElectionsPoliticsCultureSportsCryptoCommoditiesClimateEconomicsMentionsFinance

Tech & Science

PredictLive109AccountSocial
Product
Kalshi ProPerpetual FuturesMarketsIncentive programInstitutionsAPI & developers
Company
AboutKalshi ResearchBlogCareersPolicy CenterBrand Kit
Help
Help CenterFAQFee scheduleTrading hoursRegulatoryTrust Center
© 2026 Kalshi Inc. · All rights reserved
PrivacyData Terms of ServiceTrading ProhibitionsFAQ for Finance Professionals
Trading on Kalshi involves risk and may not be appropriate for all. Members risk losing their cost to enter any transaction, including fees. You should carefully consider whether trading on Kalshi is appropriate for you in light of your investment experience and financial resources. Any trading decisions you make are solely your responsibility and at your own risk. Information is provided for convenience only on an "AS IS" basis. Past performance is not necessarily indicative of future results. Kalshi is subject to U.S. regulatory oversight by the CFTC.

Medicine

All markets
AI
AI Indices
Big Tech & Business
Education
Energy
Market Share
Medicine
Physics & Math
Public Health
Space
Tokens
Eli Lilly

Will the FDA approve retatrutide?

Before Jul 1, 2027
2.14x
Before Jan 1, 2028
1.12x
$47,720 vol5 markets
Medicine

When will Compass Pathways submit a NDA for COMP360 psilocybin?

before November
2.29x
before December
1.44x
$24,187 vol4 markets
Medicine

When will the FDA reclassify BPC-157 to Category 1?

Before 2027
1.65x
Before November
11.7x
$105,792 vol2 markets
Medicine

Will the FDA approve CagriSema?

Before Jan 1, 2027
1.42x
Before Jul 1, 2027
1.23x
$7,648 vol3 markets
Biotech

FDA decision: Venglustat by Sanofi (this year)

Yes
1.14x
No
4.51x
$962 vol1 market
Biotech

FDA decision: Saroglitazar by Zydus Therapeutics (this year)

Yes
1.33x
No
2.98x
$1,180 vol1 market
Medicine

When will Beam Therapeutics submit a BLA for Risto-cel?

before 2027
1.70x
before December
2.40x
$24,926 vol4 markets
Biotech

FDA decision: Ivonescimab by Summit Therapeutics (this year)

Yes
1.76x
No
2.01x
$8,888 vol1 market
Eli Lilly

Will the FDA approve VERVE-102?

Before 2030
1.70x
Before 2031
1.42x
$1,735 vol6 markets
Medicine

Will the FDA approve a cure for Type 1 diabetes before 2033?

Yes
2.14x
No
1.62x
$10,426 vol1 market
Medicine

When will the FDA approve Intellia Therapeutics’ lonvo-z?

Before October 2027
1.09x
Before 2028
1.08x
$6,390 vol3 markets
Medicine

When will the FDA approve Compass Pathways’ COMP360 Psilocybin?

Before Mar 1, 2027
1.50x
Before Jan 1, 2027
3.40x
$23,167 vol5 markets
Biotech

FDA decision: Bepirovirsen by GlaxoSmithKline (this year)

Yes
--
No
18.8x
$4,147 vol1 market
Biotech

FDA decision: BBP-418 by Ml Bio Solutions Inc. (this year)

Yes
1.06x
No
7.85x
$836 vol1 market
Biotech

FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)

Yes
1.06x
No
7.25x
$3,669 vol1 market